Clinical Trial Update: 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of a radiolabeled anti-CD25 antibody with fludarabine, melphalan, and total marrow and lymphoid irradiation for high-risk acute leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• 90Y-DOTA-anti-CD25 Basiliximab (basiliximab)
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING